Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation-Reference-Cited by-同舟云学术

Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation

Published:2016-11-17 Issue: Volume:3 Page:
ISSN:2297-1769
Container-title:Frontiers in Veterinary Science
language:
Short-container-title:Front. Vet. Sci.

Author:

Stokol Tracy,Serpa Priscila B. D.,Zahid Muhammad N.,Brooks Marjory B.

Publisher

Frontiers Media SA

Subject

General Veterinary

Reference40 articles.

1. Equine herpesvirus-1 consensus statement;Lunn;J Vet Intern Med,2009

2. An immunohistological study of the uterus of mares following experimental infection by equid herpesvirus 1;Smith;Equine Vet J,1993

3. Infection of endothelial cells with equine herpesvirus-1 (EHV-1) occurs where there is activation of putative adhesion molecules: a mechanism for transfer of virus;Smith;Equine Vet J,2001

4. The role of endothelial cell infection in the endometrium, placenta and foetus of equid herpesvirus 1 (EHV-1) abortions;Edington;J Comp Pathol,1991

5. Abortion of virologically negative foetuses following experimental challenge of pregnant pony mares with equid herpesvirus 1;Smith;Equine Vet J,1992

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses;Journal of General Virology;2024-05-20

2. Equine Herpes Virus-1. A clinician’s perspective.;Journal of the Hellenic Veterinary Medical Society;2023-07-09

3. Activated platelets and platelet-leukocyte aggregates in the equine systemic inflammatory response syndrome;Journal of Veterinary Diagnostic Investigation;2022-02-15

4. Hypercoagulation and thrombosis associated with infection in horses;Equine Veterinary Education;2021-11-25

5. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target;International Immunopharmacology;2021-03